Literature DB >> 16166171

Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.

Thierry Dervieux1, Gary Meyer, Robert Barham, Mariko Matsutani, Mary Barry, Roselyne Boulieu, Bruce Neri, Ernest Seidman.   

Abstract

BACKGROUND: Polymorphic thiopurine S-methyltransferase (TPMT) is a major determinant of thiopurine toxicity.
METHODS: We extracted 6-thioguanine nucleotides (6-TGNs) and 6-methylmercaptopurine nucleotides (6-MMPNs) from erythrocytes with perchloric acid and converted them to 6-thioguanine (6-TG) and a 6-methylmercaptopurine (6-MMP) derivative during a 60-min acid hydrolysis step. The liquid chromatography system consisted of a C(18) column with an ammonium acetate-formic acid-acetonitrile buffer. 8-Bromoadenine was the internal standard. Analytes were measured with positive ionization and multiple reaction monitoring mode. With PCR-restriction fragment length polymorphism analysis and TaqMan allelic discrimination, common TPMT alleles (*1, *2, *3A, *3B, *3C) were determined in 31 792 individuals. We used perchloric acid extraction, acid hydrolysis, and HPLC with ultraviolet detection to measure erythrocyte 6-TG and 6-MMP nucleotide concentrations in 6189 patients with inflammatory bowel disease receiving azathioprine/6-mercaptopurine therapy.
RESULTS: Intra- and interday imprecision were <10% at low and high analyte concentrations. The conversion of 6-TG and 6-MMP nucleoside mono-, di-, and triphosphates was complete after hydrolysis. Allelic frequency for TPMT variant alleles ranged from 0.0063% (*3B) to 3.61% (*3A). Compared with wild types, TPMT heterozygotes had an 8.3-fold higher risk for 6-TGNs >450 pmol/8 x 10(8) erythrocytes (concentration associated with increased risk for leukopenia), but an 8.2-fold lower risk for 6-MMPNs >5700 pmol/8 x 10(8) erythrocytes (concentration associated with increased risk for hepatotoxicity).
CONCLUSIONS: The liquid chromatography-tandem mass spectrometry method can be applied to the routine monitoring of thiopurine therapy. The association between TPMT genotype and metabolite concentrations illustrates the utility of pharmacogenetics in the management of patients undergoing treatment with thiopurines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166171     DOI: 10.1373/clinchem.2005.050831

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  29 in total

1.  Do ITPA and TPMT genotypes predict the development of side effects to AZA?

Authors:  J A Duley; A M Marinaki; M Arenas; T H J Florin
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

2.  Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia.

Authors:  Yue Zhou; Li Wang; Xiao-Ying Zhai; Li Wen; Fang Tang; Fan Yang; Xi-Ting Liu; Lei Dong; Li-Juan Zhi; Hai-Yan Shi; Guo-Xiang Hao; Yi Zheng; Evelyne Jacqz-Aigrain; Tian-You Wang; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

3.  Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia.

Authors:  Rihwa Choi; Insuk Sohn; Min-Ji Kim; Hye In Woo; Ji Won Lee; Youngeun Ma; Eun Sang Yi; Hong Hoe Koo; Soo-Youn Lee
Journal:  Br J Clin Pharmacol       Date:  2019-05-27       Impact factor: 4.335

4.  Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn's Disease on Combination Therapy? A Multicenter Prospective Observational Study.

Authors:  Kristyna Pospisilova; Jitka Siroka; Eva Karaskova; Ondrej Hradsky; Tereza Lerchova; Kristyna Zarubova; Ivana Copova; Lucie Gonsorcikova; Maria Velganova-Veghova; Irena Francova; Lubor Urbanek; Milos Geryk; Vladimir Mihal; Jiri Bronsky
Journal:  Paediatr Drugs       Date:  2021-03-11       Impact factor: 3.022

5.  Do clinical and laboratory parameters predict thiopurine metabolism and clinical outcome in patients with inflammatory bowel diseases?

Authors:  Sven Frick; Daniel Müller; Gerd A Kullak-Ublick; Alexander Jetter
Journal:  Eur J Clin Pharmacol       Date:  2019-01-04       Impact factor: 2.953

6.  LC-MS/MS coupled with stable isotope dilution method for the quantification of 6-thioguanine and S(6)-methylthioguanine in genomic DNA of human cancer cells treated with 6-thioguanine.

Authors:  Hongxia Wang; Yinsheng Wang
Journal:  Anal Chem       Date:  2010-07-01       Impact factor: 6.986

7.  Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.

Authors:  Natalia Sutiman; Sylvia Chen; Khoon Lin Ling; Sai Wei Chuah; Wai Fook Leong; Vinayak Nadiger; Madeline Tjai; Chris San Choon Kong; Brian John Schwender; Webber Chan; Hang Hock Shim; Wee Chian Lim; Chiea Chuen Khor; Yin Bun Cheung; Balram Chowbay
Journal:  Pharmacogenomics       Date:  2017-12-06       Impact factor: 2.533

8.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

9.  Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT*3C.

Authors:  Mi-Na Lee; Hye In Woo; Yoo Min Lee; Ben Kang; Jong-Won Kim; Yon Ho Choe; Soo-Youn Lee
Journal:  Yonsei Med J       Date:  2013-11       Impact factor: 2.759

10.  Thiopurines with low-dose allopurinol (ThiLDA)-a prospective clinical one-way crossover trial.

Authors:  S Faraz Chavoushi; Bindia Jharap; Philip Friedrich; Kees Smid; Godefridus J Peters; Mirte Malingré
Journal:  Eur J Clin Pharmacol       Date:  2019-10-05       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.